Neimeth International Pharmaceuticals Plc (NGX: NEIMETH)
Nigeria
· Delayed Price · Currency is NGN
2.180
0.00 (0.00%)
At close: Nov 29, 2024
NEIMETH Income Statement
Financials in millions NGN. Fiscal year is January - December.
Millions NGN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 - 2015 |
Revenue | 3,793 | 2,210 | 2,919 | 2,703 | 3,047 | 2,839 | Upgrade
|
Revenue Growth (YoY) | 97.62% | -24.31% | 8.01% | -11.28% | 7.31% | 19.73% | Upgrade
|
Cost of Revenue | 2,216 | 1,500 | 1,886 | 1,629 | 1,622 | 1,348 | Upgrade
|
Gross Profit | 1,577 | 709.15 | 1,033 | 1,074 | 1,425 | 1,491 | Upgrade
|
Selling, General & Admin | 1,444 | 1,636 | 1,204 | 1,125 | 1,074 | 938.84 | Upgrade
|
Other Operating Expenses | -157.44 | -157.38 | -157.95 | -26.15 | -197.17 | -145.91 | Upgrade
|
Operating Expenses | 1,287 | 1,478 | 1,046 | 1,099 | 876.42 | 792.93 | Upgrade
|
Operating Income | 290.36 | -769.05 | -12.39 | -24.8 | 548.74 | 697.94 | Upgrade
|
Interest Expense | -886.26 | -667.95 | -300 | -181.77 | -188.22 | -212.76 | Upgrade
|
Interest & Investment Income | 173.89 | 129.23 | - | - | - | - | Upgrade
|
Currency Exchange Gain (Loss) | -1,454 | -1,451 | 1.94 | 96.89 | -0.09 | -188.05 | Upgrade
|
EBT Excluding Unusual Items | -1,876 | -2,758 | -310.45 | -109.67 | 360.43 | 297.13 | Upgrade
|
Gain (Loss) on Sale of Assets | 0.97 | 0.97 | - | - | 4.86 | - | Upgrade
|
Pretax Income | -1,875 | -2,757 | -310.44 | -109.66 | 365.28 | 297.39 | Upgrade
|
Income Tax Expense | 107.88 | 107.88 | 14.6 | - | 94.71 | 84.91 | Upgrade
|
Net Income | -1,983 | -2,865 | -325.04 | -109.66 | 270.58 | 212.48 | Upgrade
|
Net Income to Common | -1,983 | -2,865 | -325.04 | -109.66 | 270.58 | 212.48 | Upgrade
|
Net Income Growth | - | - | - | - | 27.34% | -3.48% | Upgrade
|
Shares Outstanding (Basic) | 4,273 | 4,273 | 1,899 | 1,899 | 1,899 | 1,899 | Upgrade
|
Shares Outstanding (Diluted) | 4,273 | 4,273 | 1,899 | 1,899 | 1,899 | 1,899 | Upgrade
|
Shares Change (YoY) | 16.13% | 125.00% | - | - | - | - | Upgrade
|
EPS (Basic) | -0.46 | -0.67 | -0.17 | -0.06 | 0.14 | 0.11 | Upgrade
|
EPS (Diluted) | -0.46 | -0.67 | -0.17 | -0.06 | 0.14 | 0.11 | Upgrade
|
EPS Growth | - | - | - | - | 27.34% | -3.48% | Upgrade
|
Free Cash Flow | -377.26 | -1,710 | -1,137 | -1,205 | 1.96 | -261.53 | Upgrade
|
Free Cash Flow Per Share | -0.09 | -0.40 | -0.60 | -0.63 | 0.00 | -0.14 | Upgrade
|
Dividend Per Share | - | - | - | - | 0.070 | 0.065 | Upgrade
|
Dividend Growth | - | - | - | - | 7.69% | - | Upgrade
|
Gross Margin | 41.58% | 32.09% | 35.39% | 39.74% | 46.78% | 52.51% | Upgrade
|
Operating Margin | 7.66% | -34.81% | -0.42% | -0.92% | 18.01% | 24.58% | Upgrade
|
Profit Margin | -52.28% | -129.68% | -11.13% | -4.06% | 8.88% | 7.48% | Upgrade
|
Free Cash Flow Margin | -9.95% | -77.37% | -38.95% | -44.57% | 0.06% | -9.21% | Upgrade
|
EBITDA | 438.15 | -642.96 | 96.02 | 94.78 | 639.06 | 808.66 | Upgrade
|
EBITDA Margin | 11.55% | -29.10% | 3.29% | 3.51% | 20.98% | 28.48% | Upgrade
|
D&A For EBITDA | 147.78 | 126.09 | 108.41 | 119.57 | 90.32 | 110.72 | Upgrade
|
EBIT | 290.36 | -769.05 | -12.39 | -24.8 | 548.74 | 697.94 | Upgrade
|
EBIT Margin | 7.66% | -34.81% | -0.42% | -0.92% | 18.01% | 24.58% | Upgrade
|
Effective Tax Rate | - | - | - | - | 25.93% | 28.55% | Upgrade
|
Advertising Expenses | - | 363.67 | - | 188.49 | 224.46 | 156.24 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.